A- A A+

HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. 

Korthuis, PT, Cook, RR, Lum, PJ, Waddell, EN, Tookes, H, Vergara-Rodriguez, P, et al. 

Addiction. 2022; 117: 1961– 1971. doi.org/10.1111/add.15836


Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials. 

Shulman M, Hu MC, Sullivan MA, Akerman SC, Fratantonio J, Barbieri V, Nunes EV, Bisaga A. 

Drug Alcohol Depend. 2022 Apr 1;233:109343. doi: 10.1016/j.drugalcdep.2022.109343. Epub 2022 Feb 2. PMID: 35131528; PMCID: PMC8957614.


Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018. 

Jain P, McKinnell K, Marino R, Vunnava P, Liles-Burden MA, Desai A, Wenten M, Fratantonio J, Akerman SC, Sullivan MA, Bloomgren G. 

Drug Saf. 2021 Mar;44(3):351-359. doi: 10.1007/s40264-020-01020-4. Epub 2020 Nov 30. PMID: 33258068; PMCID: PMC7892734.


Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment. 

Biondi BE, Frank CA, Forray A, Springer SA. 

Subst Abus. 2021;42(4):905-911. doi: 10.1080/08897077.2021.1900984. Epub 2021 Mar 22. PMID: 33750285; PMCID: PMC8455717.


Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials. 

Shulman M, Hu MC, Sullivan MA, Akerman SC, Fratantonio J, Barbieri V, Nunes EV, Bisaga A. 

Drug Alcohol Depend. 2022 Feb 2;233:109343. doi: 10.1016/j.drugalcdep.2022.109343. Epub ahead of print. PMID: 35131528.


Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes. 

Makarenko I, Pykalo I, Springer SA, Mazhnaya A, Marcus R, Filippovich S, Dvoriak S, Altice FL. 

J Subst Abuse Treat. 2019 Sep;104:34-41. doi: 10.1016/j.jsat.2019.05.008. Epub 2019 May 10. PMID: 31370983; PMCID: PMC8215516.


Naltrexone Implant for Opioid Use Disorder. 

Edinoff AN, Nix CA, Orellana CV, StPierre SM, Crane EA, Bulloch BT, Cornett EM, Kozinn RL, Kaye AM, Murnane KS, Kaye AD. 

Neurol Int. 2021 Dec 30;14(1):49-61. doi: 10.3390/neurolint14010004. PMID: 35076607; PMCID: PMC8788412.


'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study. 

Brenna IH, Marciuch A, Birkeland B, Veseth M, Røstad B, Løberg EM, Solli KK, Tanum L, Weimand B. 

J Subst Abuse Treat. 2021 Nov 27:108667. doi: 10.1016/j.jsat.2021.108667. Epub ahead of print. PMID: 34865937.


Opioid antagonism modulates wanting-related frontostriatal connectivity. 

Soutschek A, Weber SC, Kahnt T, Quednow BB, Tobler PN. 

Elife. 2021 Nov 11;10:e71077. doi: 10.7554/eLife.71077. PMID: 34761749; PMCID: PMC8598157.


Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. 

Hoffman KA, Baker R, Fanucchi LC, Lum PJ, Kunkel LE, Ponce Terashima J, McCarty D, Jacobs P, Korthuis PT. 

Addict Sci Clin Pract. 2021 Nov 10;16(1):67. doi: 10.1186/s13722-021-00277-z. PMID: 34758887; PMCID: PMC8579672.


Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up

Gaulen, Zhanna et al.

Journal of Substance Abuse Treatment, Volume 0, Issue 0, 108656 


Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. 

Roache, J.D., Pavlicova, M., Campbell, A., Choo, T.-H., Peavy, M., Kermack, A.S., Nunes, E.V., Jr. and Rotrosen, J. (2021), 

Alcoholism: Clinical and Experimental Research. Accepted Author Manuscript. doi.org/10.1111/acer.14729


Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone. 

Karlsson AT, Vederhus JK, Clausen T, Weimand B, Solli KK, Tanum L. 

J Clin Med. 2021 Sep 30;10(19):4558. doi: 10.3390/jcm10194558. PMID: 34640572; PMCID: PMC8509800.


Low-Dose Naltrexone Co-Treatment in the Prevention of Opioid-Induced Hyperalgesia. 

Shaheed G, Manjooran AP, Reddy AJ, Nawathey N, Habib S, Brahmbhatt H. 

Cureus. 2021 Sep 2;13(9):e17667. doi: 10.7759/cureus.17667. PMID: 34646707; PMCID: PMC8487298.


The impact of age and genetics on naltrexone biotransformation. 

Stancil SL, Nolte W, Pearce RE, Staggs VS PhD, Leeder JS. 

Drug Metab Dispos. 2021 Nov 2:DMD-AR-2021-000646. doi: 10.1124/dmd.121.000646. Epub ahead of print. PMID: 34728519.


Adverse drug reactions with naltrexone: Experience from an addiction treatment center. 

Sarkar S, Addagadda SS, Bhatia G, Chadda RK. 

Indian J Psychiatry. 2021 Mar-Apr;63(2):206-207. doi: 10.4103/psychiatry.IndianJPsychiatry_94_20. Epub 2021 Apr 14. PMID: 34194072; PMCID: PMC8214125.


Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. 

Kosten T, Aharonovich E, Nangia N, Zavod A, Akerman SC, Lopez-Bresnahan M, Sullivan MA. 

Addict Behav. 2020 Dec;111:106538. doi: 10.1016/j.addbeh.2020.106538. Epub 2020 Jul 3. PMID: 32777606.


Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder. 

Perez-Macia V, Martinez-Cortes M, Mesones J, Segura-Trepichio M, Garcia-Fernandez L. 

Patient Prefer Adherence. 2021 May 18;15:999-1015. doi: 10.2147/PPA.S277861. PMID: 34040354; PMCID: PMC8140930.


Life threatening opioid withdrawal syndrome due to inadvertent naltrexone administration and lifesaving result by clonidine. 

Kurmi J, Choudhury HA. 

Indian J Psychiatry. 2020 Nov-Dec;62(6):742-743. doi: 10.4103/psychiatry.IndianJPsychiatry_649_19. Epub 2020 Dec 12. PMID: 33896990; PMCID: PMC8052871.


Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial

Collins, Susan E et al.

The Lancet Psychiatry, Volume 8, Issue 4, 287 - 300 


Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study). 

Weimand BM, Solli KK, Reichelt WH, Tanum L. 

Contemp Clin Trials Commun. 2021 Feb 10;21:100728. doi: 10.1016/j.conctc.2021.100728. PMID: 33665469; PMCID: PMC7900681.


A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. 

Sibai M, Mishlen K, Nunes EV, Levin FR, Mariani JJ, Bisaga A. 

Am J Drug Alcohol Abuse. 2020 May 3;46(3):289-296. doi: 10.1080/00952990.2019.1700265. Epub 2019 Dec 20. PMID: 31860366; PMCID: PMC7260104.


Adapting treatment length to opioid‐dependent individuals’ needs and preferences: a 2‐year follow‐up to a 1‐year study of extended‐release naltrexone. 

Solli, K. K., Opheim, A., Latif, Z., Krajci, P., Benth, Jė. Š., Kunoe, N., and Tanum, L. (2021) 

Addiction, doi.org/10.1111/add.15378.


Naltrexone-Associated Non-ST-Elevated Myocardial Infarction. 

Gubitosa JC, Terwillliger T, Ukazu A, Gordon E. 

Cureus. 2020 Oct 27;12(10):e11198. doi: 10.7759/cureus.11198. PMID: 33269129; PMCID: PMC7703987.


Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management. 

Sadee W, Oberdick J, Wang Z. 

Molecules. 2020 Sep 11;25(18):E4163. doi: 10.3390/molecules25184163. PMID: 32932935.


Naloxone-Induced Acute Opioid Withdrawal in a Stabilized Extended-Release Naltrexone-Treated Patient. 

Spitzberg AJ, Urner EM, Wirshing WC. 

Prim Care Companion CNS Disord. 2020 Sep 17;22(5):20l02590. doi: 10.4088/PCC.20l02590. PMID: 32942347.


Improving naltrexone compliance and outcomes with putative pro-dopamine regulator KB220, compared to treatment as usual. 

Blum K, Lott L, Baron D, Smith DE, Badgaiyan RD, Gold MS. 

J Syst Integr Neurosci. 2020 May 30;7:10.15761/JSIN.1000229. doi: 10.15761/JSIN.1000229. PMID: 32934823; PMCID: PMC7489288.


Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. 

Krieter P, Gyaw S, Chiang CN, Crystal R, Skolnick P.  

J Clin Pharmacol. 2019;59(7):947-957. doi:10.1002/jcph.1384


Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. 

Kosten T, Aharonovich E, Nangia N, et al. 

Addict Behav. 2020;111:106538. doi:10.1016/j.addbeh.2020.106538


Letter To The Editor - Drug Eruption After Sustained Release Naltrexone Pellet Implantation -- Editöre Mektup - Yavaş Salınımlı Naltrekson İmplant Uygulaması Sonrası Gelişen İlaç Erüpsiyonu.

Ak S, Can Gürel Ş. 

Turk Psikiyatri Derg. 2020;31(2):146-147.